Aytu BioPharma Inc. (AYTU) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for AYTU, including 2 SEC filings. The most recent was published Oct 27, 2026.
Financial highlights
Full financials- Revenue, FY2026
- $57.57M
- Revenue growth
- -13.3%
- Net income, FY2026
- -$14.25M
- Net margin
- -24.8%
- Free cash flow, FY2026
- $3.25M
- Cash
- $26.31M
For fiscal 2026 (ended Jun 30, 2026), from SEC filings. Not investment advice.
News · 26 weeks21-50%
2026-05-102026-11-01
Mix790d
- SEC Filings4(57%)
- Market2(29%)
- Other1(14%)
Latest news
25 items- SECSEC Form DEFA14A filed by Aytu BioPharma Inc.DEFA14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECSEC Form DEF 14A filed by Aytu BioPharma Inc.DEF 14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECSEC Form 10-K filed by Aytu BioPharma Inc.10-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial ResultsFourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026$26.3 million cash balance at June 30, 2026Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Ay
- NEWSAytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Tuesday, September 22, 2026, at 4:30 p.m. East
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- INSIDERChief Commercial Officer Pyszczymuka Greg was granted 20,000 shares, increasing direct ownership by 55% to 56,102 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Executive Officer Disbrow Joshua R. was granted 30,000 shares, increasing direct ownership by 14% to 237,203 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Business Officer Disbrow Jarrett was granted 15,000 shares, increasing direct ownership by 24% to 76,568 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Financial Officer Selhorn Ryan J was granted 25,000 shares, increasing direct ownership by 50% to 74,743 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Liu Vivian H was granted 10,000 shares, increasing direct ownership by 50% to 29,825 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Jain Abhinav was granted 10,000 shares, increasing direct ownership by 51% to 29,500 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Dockery Carl was granted 10,000 shares, increasing direct ownership by 47% to 31,152 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Donofrio John Jr. was granted 10,000 shares, increasing direct ownership by 73% to 23,762 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.To access the live webcast, please use the following information:Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClubDate: Wednesday, June 17,
- NEWSAytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.Company WebcastThe webcast presentation will take place at 9:15 a.m. Eastern time on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.w
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial ResultsEXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth ratesTotal net revenue of $12.4 millionAdjusted EBITDA1 of $(2.8) million, which includes EXXUA™ (gepirone) extended-release tablets ("EXXUA") launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ("MDD") market$26.7 million cash balance at March 31, 2026Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / May 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company
- NEWSAytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time.Call-in Information: I
- SECAytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
AYTU FAQ
10 questionsWhat does Aytu BioPharma Inc. do?
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal...What is the latest news on AYTU?
In the last 30 days Quantisnow tracked 2 wire items for AYTU: 2 SEC filings. The most recent was published on October 27, 2026.What is AYTU revenue?
Aytu BioPharma Inc. (AYTU) reported $57.57M of revenue for fiscal 2026 (ended Jun 30, 2026). That is down 13.3% from the year before.Is AYTU profitable?
No. Aytu BioPharma Inc. reported a net loss of $14.25M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does AYTU have?
Aytu BioPharma Inc. reported $26.31M in cash and cash equivalents and $10.96M of debt on its most recent balance sheet in SEC filings.Where does AYTU stock trade?
Aytu BioPharma Inc. (AYTU) is listed on NASDAQ.What sector and industry is AYTU in?
Aytu BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AYTU?
Aytu BioPharma Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $8.00 price target on 2025-07-01. Recent price targets range from $8.00 to $12.00.What companies are similar to AYTU?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AYTU side-by-side with any of them on Quantisnow.How can I track AYTU on Quantisnow?
Quantisnow aggregates Aytu BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AYTU to receive live email and push alerts on every new disclosure.